Ripharma Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-07-2024
- Paid Up Capital ₹ 0.50 M
as on 31-07-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 13.09%
(FY 2023)
- Profit 91.91%
(FY 2023)
- Ebitda 80.60%
(FY 2023)
- Net Worth 39.15%
(FY 2023)
- Total Assets 37.00%
(FY 2023)
About Ripharma Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Shreepal Jain, Shrenik Jain, Milan Jain, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24100MH2015PLC262970
- Company No.
262970
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
25 Mar 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ripharma Laboratories?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishabh Jain  | Director | 25-Mar-2015 | Current |
| Shreepal Jain | Director | 25-Mar-2015 | Current |
| Shrenik Jain | Director | 25-Mar-2015 | Current |
| Milan Jain | Director | 25-Mar-2015 | Current |
| Amit Jain | Director | 25-Mar-2015 | Current |
Financial Performance of Ripharma Laboratories.
Ripharma Laboratories Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.09% increase. The company also saw a substantial improvement in profitability, with a 91.91% increase in profit. The company's net worth Soared by an impressive increase of 39.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ripharma Laboratories?
In 2023, Ripharma Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rishabh Indotex LimitedActive 20 years 8 monthsShreepal Jain, Shrenik Jain and 1 more are mutual person
- Skyline Construtech Private LimitedActive 12 years 2 months
Shreepal Jain, Shrenik Jain and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ripharma Laboratories?
Unlock and access historical data on people associated with Ripharma Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ripharma Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ripharma Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
